TELA TELA Bio

TELA Bio to Announce First Quarter 2020 Financial Results and Host Conference Call on May 12, 2020

TELA Bio to Announce First Quarter 2020 Financial Results and Host Conference Call on May 12, 2020

MALVERN, Pa., April 28, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 first quarter financial results on Tuesday, May 12, 2020. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. 

Conference Call and Webcast Details

The conference call can be accessed by dialing (855) 548-1219 for participants in the U.S. or Canada and (409) 217-8881 for international callers, using conference ID 8079329. A live and archived webcast of the event can be accessed via the page of the investor section of TELA's website.

About TELA Bio, Inc.

TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA Bio's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA Bio's portfolio is supported by quality, data-driven science, and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

TELA Bio Contact

Stuart Henderson

Vice President, Corporate Development and Investor Relations

TELA Bio, Inc.

484-320-2930



Investor Contact

Greg Chodaczek

347-620-7010 

EN
28/04/2020

Underlying

TELATELA Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TELA Bio

 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Confer...

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA’s management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, Inc.TELA Bio, ...

May 22, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuan...

May 9, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Reports First Quarter 2025 Financial Results

TELA Bio Reports First Quarter 2025 Financial Results MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix product...

May 8, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio to Announce First Quarter 2025 Financial Results

TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...

April 17, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...

TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...

March 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch